However, as observed with many T2DM medications, adherence is a major problem with GLP-1 RAs with reported discontinuation in real-world scenarios to be approximately 45% at 1 year [28,29] due to unwanted side effects [30], high cost [31], and unwillingness to follow the physician’s treatment advice [32]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.